5亿产业基金重磅落地 呼和浩特生物医药产业集群再迎战略风口

Core Insights - The establishment of the Inner Mongolia Hohhot Biomedical Industry High-Quality Development Fund and China Resources Double Crane Industry Fund has been officially registered, with an initial scale of 500 million yuan, focusing on high-tech project transformation in synthetic biology, innovative drugs, and biotechnology [1][4] - The fund aims to serve as an "industry empowerment investment platform," providing not only financial support but also leveraging China Resources Group's diverse industrial resources to assist local enterprises in technology R&D, pilot transformation, capacity implementation, and market expansion [1][4] Investment Focus - The fund is centered around the core track of synthetic biology, focusing on three main areas: 1. Fundamental technology innovation, including microbial strain construction, intelligent design of cell factories, and core enzyme preparation research [2] 2. Industrialization of end products, targeting biobased raw material intermediates, functional new foods, biobased new materials, and green agriculture with evident market potential [2] 3. Supporting the industrial ecosystem by investing in R&D services and AI molecular design to empower upstream and downstream enterprises in the synthetic biology industry [2] Local Industry Development - Hohhot is leveraging its unique resource endowments and comparative advantages to build a biomedical industry cluster characterized by synthetic biology, forming a complete industrial chain including biomanufacturing, biological vaccines, and traditional Chinese medicine [4] - The city currently has 34 large-scale industrial enterprises and has obtained 602 drug registration approvals, showcasing continuous industrial agglomeration effects and development vitality [4] - The launch of the 500 million yuan fund is expected to further enhance the local biomedical industry's supply chain, accelerate the transformation from "resource advantages" to "development advantages," and narrow the gap with top national biomedical industry clusters [4][5]